L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:354825 CAPLUS Full-text
DN 143:199747
TI **Polymorphous** forms of rifaximin, processes for their production and use thereof in medicinal preparations
IN Viscomi, Giuseppe C.; Campana, Manuela; Braga, Dario; Confortini, Donatella; Cannata, Vincenzo; Severini, Denis; Righi, Paolo; Rosini, Goggredo
PA Alfa Wassermann S, Italy
SO N.Z., 27 pp.
CODEN: NZXXBT
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NZ 531622	A	20041029	NZ 2004-531622	20040309
US 2005101598	A1	20050512	US 2003-728090	20031205
CA 2460384	AA	20050507	CA 2004-2460384	20040309
EP 1557421	A1	20050727	EP 2004-5541	20040309
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
ZA 2004001948	A	20040429	ZA 2004-1948	20040310
JP 2005139161	A2	20050602	JP 2004-76458	20040317
BR 2004002382	A	20050628	BR 2004-2382	20040319
WO 2005044823	A2	20050519	WO 2004-EP12490	20041104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI IT 2003-MI2144	A	20031107		

AB Disclosed herein are α, β, and γ **polymorphous** forms of rifaximin, wherein the formation of the α, β, and γ forms depends on the presence of water within the **crystn** . solvent, on the temperature at which the product is **crystallized** and the amount of water present into the product at the end of the drying phase. Processes for the production of α, β, and γ **polymorphs** of rifaximin and their pharmaceutical compns. are also disclosed. Thus, raw rifaximin 89.2 g and Et alc. 170 mL were loaded at room temperature into a three-necked flask equipped with mechanic stirrer, thermometer and reflux condenser, then the suspension was heated at 57 ± 3°C until complete dissoln. of the solid. The temperature was brought to 50°C and then demineralized water 51.7 mL were added at this temperature during 30 min. After the end of the addition the temperature was brought to 30°C in one hour and the suspension was kept for 30 min at this temperature obtaining a plentiful **crystallization** The temperature of the suspension was brought to 40°C and kept at this value during 20 h under stirring and then further lowered to 0°C during 30 min after which the suspension was immediately filtered. The solid was washed with 240 mL of demineralized water and dried under vacuum at 65°C until constant weight obtaining rifaximin α 46.7 g with a water content equal to 2.5 %.

IT **80621-81-4P**, Rifaximin
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(processes for the production of **polymorphous** forms of rifaximin for pharmaceutical preparation)

RN 80621-81-4 CAPLUS

CN 2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1992:433790 CAPLUS Full-text
DN 117:33790
TI Application of near-infrared reflectance spectroscopy (NIRS) to several antibiotic compounds
AU Corti, P.; Savini, L.; Dreassi, E.; Petriconi, S.; Genga, R.; Montecchi, L.; Lonardi, S.
CS Dip. Farm. Chim. Tecnol., Univ. Siena, Siena, 53100, Italy
SO Process Control and Quality (1992), 2(2), 131-42
CODEN: PCQUEJ; ISSN: 0924-3089
DT Journal
LA English
AB The possibility of applying near-IR reflectance spectroscopy (NIRS) to the qual. and quant. control of several antibiotics was investigated. Samples of amorphous sodium ampicillin, gentamycin sulfate, erythromycin ethylsuccinate, erythromycin stearate, amorphous miokamycin and rifaximin were analyzed. Some were analyzed as primary material, others half-processed (erythromycin ethylsuccinate in granules at different concns. of active ingredient) and others as the finished pharmaceutical product (rifaximin cream). The results were both qual. and quant. satisfactory. The distinction between amorphous or **crystalline** sodium ampicillin and ampicillin trihydrate and between the different erythromycin ethyl succinate granules was interesting. It was confirmed that NIRS can be successfully applied to the quant. control of solid and fluid (e.g. rifaximin cream) antibiotics forms.
IT **80621-81-4**, Rifaximin
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in pharmaceuticals, by near-IR reflectance spectroscopy)
RN 80621-81-4 CAPLUS
CN 2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1984:503607 CAPLUS Full-text
DN 101:103607
TI Structure-activity relationships in 4-deoxypyrido(1',2'-1,2)imidazo(5,4-c)rifamycin SV derivatives
AU Cellai, L.; Cerrini, S.; Brufani, M.; Marchi, E.; Mascellani, G.; Montecchi, L.
CS Ist. Strutt. Chim. "G. Giacomello", Rome, Italy
SO Chemioterapia (1983), 2(5, Suppl.: Mediterr. Congr. Chemother., Proc., 3rd, 1982), 53-4
CODEN: CHEMEV; ISSN: 0392-906X
DT Journal
LA English
GI



I

AB The polarity of rifamycin L-105 SV (I) [**80621-81-4**] and its oxidized S [80621-76-7] form and the contribution of this polarity in the pharmacokinetics of these drugs were investigated. NMR and x-ray **crystallog.** studies indicated that the pyridoimidazo ring is coplanar with the naphthoquinonic nucleus making the pyridoimidazo ring system aromatic with the 2 N both charged. The pyrido-N is pos. charged and the other neg. charged. The contribution of charged forms to the resonance-structure of these compds. renders these agents with pharmacokinetic properties that make them virtually nonabsorbable from the intestine and thus providing high antimicrobial activity in the digestive tract.

IT **80621-81-4**
RL: PROC (Process)
(absorption of, by intestine, structure in relation to)

RN 80621-81-4 CAPLUS
CN 2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)- (9CI) (CA INDEX NAME)



```
=> d his; log y

     (FILE 'HOME' ENTERED AT 19:39:26 ON 15 SEP 2005)

     FILE 'REGISTRY' ENTERED AT 19:39:35 ON 15 SEP 2005
L1             1 S RIFAXIMIN/CN

     FILE 'REGISTRY' ENTERED AT 19:40:29 ON 15 SEP 2005
L2             1 S 80621-81-4/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'CAPLUS' ENTERED AT 19:41:10 ON 15 SEP 2005
L3           125 S L2
L4           125 S L1
L5             3 S L4 AND (CRYSTAL? OR POLYMOR?)


COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                19.50      29.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -2.19      -2.19

STN INTERNATIONAL LOGOFF AT 19:42:22 ON 15 SEP 2005
```